SynthesisPediatric dermatology
Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review.
Synthesis in Pediatric dermatology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Janus Kinase Inhibitors for the Treatment of Pediatric Morphea: A Systematic Review.Pediatric dermatologyPooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Morphea, also known as localized scleroderma (LoS), is an inflammatory, fibrosing dermatologic disorder of the skin and underlying tissues with associated comorbidities including joint contractures, limb-length discrepancies, and inflammatory arthropathy occurring more commonly in children. While standardized consensus treatment plans for pediatric LoS have been developed by the Childhood Arthritis and Rheumatology Research Alliance, the use of Janus kinase (JAK) inhibitors in the treatment of pediatric LoS has recently been reported. This review, which systematically summarizes the published literature on the use of oral and topical JAK inhibitors for pediatric LoS, identified nine studies (involving 16 patients across all studies) that met inclusion criteria with improvement following JAK inhibitor initiation reported in 94% (n = 15) of cases. Overall, these findings demonstrate that JAK inhibitors may offer a promising alternative to treat pediatric morphea; however, more robust studies are required to evaluate the efficacy of JAK inhibitors in treating pediatric LoS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.